IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – Should You Buy?

Shares of IPSEN (OTCMKTS:IPSEY) saw strong trading volume on Friday . 7,390 shares traded hands during mid-day trading, an increase of 117% from the previous session’s volume of 3,412 shares.The stock last traded at $45.84 and had previously closed at $44.1425.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IPSEY shares. BNP Paribas Exane cut IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. UBS Group lowered IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN has an average rating of “Hold”.

IPSEN Stock Performance

The company’s 50 day moving average is $37.61 and its 200-day moving average is $35.43.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).